| scholarly article | Q13442814 |
| P2093 | author name string | Martin J Bergman | |
| Eric P Elkin | |||
| Tripthi Kamath | |||
| Sarika Ogale | |||
| Max I Hamburger | |||
| P2860 | cites work | RAPID3 (Routine Assessment of Patient Index Data 3), a rheumatoid arthritis index without formal joint counts for routine care: proposed severity categories compared to disease activity score and clinical disease activity index categories | Q33369498 |
| DAS-28-based EULAR response and HAQ improvement in rheumatoid arthritis patients switching between TNF antagonists | Q33486150 | ||
| Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent? | Q33566367 | ||
| RAPID3 (Routine Assessment of Patient Index Data 3) severity categories and response criteria: Similar results to DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) in the RAPID 1 (Rheumatoid Arthritis Prevention of Structural | Q33870130 | ||
| Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period | Q34896269 | ||
| Rituximab is more effective than second anti-TNF therapy in rheumatoid arthritis patients and previous TNFα blocker failure | Q36108479 | ||
| Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review | Q37158791 | ||
| RAPID3-an index of physical function, pain, and global status as "vital signs" to improve care for people with chronic rheumatic diseases. | Q37543513 | ||
| Clinical relevance of switching to a second tumour necrosis factor-alpha inhibitor after discontinuation of a first tumour necrosis factor-alpha inhibitor in rheumatoid arthritis: a systematic literature review and meta-analysis. | Q37832555 | ||
| Optimizing outcomes in patients with rheumatoid arthritis and an inadequate response to anti-TNF treatment | Q38020460 | ||
| Comparative effectiveness of cycling of tumor necrosis factor-α (TNF-α) inhibitors versus switching to non-TNF biologics in rheumatoid arthritis patients with inadequate response to TNF-α inhibitor using a Bayesian approach | Q38182440 | ||
| Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: the MIRAR Study | Q46073200 | ||
| Use of tumor necrosis factor inhibitors in rheumatoid arthritis: a national survey of practicing United States rheumatologists. | Q52006320 | ||
| Guidelines for the management of rheumatoid arthritis: 2002 Update | Q56212157 | ||
| B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents | Q80238326 | ||
| Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice | Q80340995 | ||
| Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register | Q80785522 | ||
| Which subgroup of rheumatoid arthritis patients benefits from switching to tocilizumab versus etanercept after previous infliximab failure? A retrospective study | Q84459290 | ||
| P433 | issue | 1 | |
| P921 | main subject | rheumatoid arthritis | Q187255 |
| P304 | page(s) | 21-30 | |
| P577 | publication date | 2014-09-23 | |
| P1433 | published in | Rheumatology and therapy | Q27727370 |
| P1476 | title | Response to Biologic Disease-Modifying Anti-Rheumatic Drugs after Discontinuation of Anti-Tumor Necrosis Factor Alpha Agents for Rheumatoid Arthritis | |
| P478 | volume | 1 |
| Q39068415 | Outcomes of tumor necrosis factor inhibitor cycling versus switching to a disease-modifying anti-rheumatic drug with a new mechanism of action among patients with rheumatoid arthritis |
| Q88443607 | Treatment Persistence and Clinical Outcomes of Tumor Necrosis Factor Inhibitor Cycling or Switching to a New Mechanism of Action Therapy: Real-world Observational Study of Rheumatoid Arthritis Patients in the United States with Prior Tumor Necrosis |
| Q64924368 | Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis After a Change in Targeted Therapy. |
| Q47131401 | Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis Changing Biologics in the USA. |
Search more.